The week in industry: FDA accepts NDAs for two antibacterial agents from Merck
This week: Kalytera announce positive results in their ongoing CBD study, Recordati gains rights to commercialize JUXTAPID® in Japan and MS patients under Medicare paying more out-of-pocket for treatments.
Please sign in or register for FREE
Sign in to RxNet
Not yet a member? Become a member FREE to:
- Get unlimited access to ALL CONTENT
- Read selected articles from journals such as Future Medicinal Chemistry FREE
- Receive a weekly email roundup of the latest news and expert opinions
Did you know?
Your RxNet account also gives you access to communities on regenerative medicine, real-world evidence and 3D printing in medicine. Find out more>>